Cita APA (7a ed.)

M, T., G, O., G, T., C, W., MCT, F., A, R., . . . A, D. (2019). A phase 2 randomized, double-masked, placebo-controlled study of novel nonsystemic kinase inhibitor TOP1630 for the treatment of dry eye disease. Dove Medical Press.

Cita Chicago Style (17a ed.)

M, Taylor, Ousler G, Torkildsen G, Walshe C, Fyfe MCT, Rowley A, Webber S, Sheppard JD, y Duggal A. A Phase 2 Randomized, Double-masked, Placebo-controlled Study of Novel Nonsystemic Kinase Inhibitor TOP1630 for the Treatment of Dry Eye Disease. Dove Medical Press, 2019.

Cita MLA (8a ed.)

M, Taylor, et al. A Phase 2 Randomized, Double-masked, Placebo-controlled Study of Novel Nonsystemic Kinase Inhibitor TOP1630 for the Treatment of Dry Eye Disease. Dove Medical Press, 2019.